Evidence of a role for cyclic ADP-ribose in calcium signaling and migration in human neutrophils

环 ADP-核糖在人中性粒细胞钙信号传导和迁移中作用的证据

基本信息

  • 批准号:
    15591967
  • 负责人:
  • 金额:
    $ 1.92万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2003
  • 资助国家:
    日本
  • 起止时间:
    2003 至 2004
  • 项目状态:
    已结题

项目摘要

Cyclic ADP-ribose (cADPR) has a powerful Ca^<2+>-mobilizing action and behaves as a second messenger of many agonists, thereby modulating a wide number of Ca^<2+>-mediated cell processes. CD38, the best-characterized mammalian ADP-ribosyl cyclase, is postulated to be an important source of cADPR in vivo. Although an increase in [Ca^<2+>]i is a key signal neutrophil functions, the mechanisms for regulation of [Ca^<2+>]i is unclear. The present study examined the regulation by cADPR of Ca^<2+> dynamics and its physiological role in human neutrophils.cADPR induced Ca^<2+> release from digitonin-permeabilized neutrophils and the release was blocked by 8Br-cADPR, an antagonist of cADPR and FK506 and rapamycin. fMLP and PAF induced a initial rapid rise of [Ca^<2+>]i and the following sustained rise in intact neutrophils. β-NAD^+ added into the medium increased [Ca^<2+>]i. Chemoattractans- and β-NAD^+-induced [Ca^<2+>]i rise were reduced by 8Br-cADPR, anti-CD38 antibody, FK506, rapamycin, NAD … More ase and several nucleoside transporter (NT) inhibitors. ENT_1, ENT_2, CNT_2, CNT_3 are expressed in neutrophils. These results suggest that cADPR synthesized extracellulary by CD38 transported into the cells through NTs and mobilize Ca^<2+> by FK506-binding protein-dependent process and is required for sustained Ca^<2+> influx in neutrophils.Pretreatment of human neutrophils with either EGTA or 8Br-cADPR specifically blocked the chemotsxis stimulated with fMLP or PAF. Likewise, treatment of neutrophils with FK506, anti-CD38 antibody, NADase and NT inhibitors blocked the chemotaxis to fMLP or PAF. These results demonstrate that neutrophil chemotaxis to fMLP and PAF are dependent on Ca^<2+> mobilization mediated by cADPR.Thus, cADPR controls neutrophil chemotaxis to chemoattractants through its production of cADPR, and acts as a critical regulator of inflammation and innate immune responses. Since many of the chemoattractant receptors regulated by cADPR bind to ligands that are associated with clinical pathology, cADPR, CD38 and NTs represent novel drug targets with potential application in chronic inflammatory and neurodegenerative disease. Less
循环ADP -ribose(CADPR)具有强大的Ca^<2+> - 动作,并作为许多激动剂Ca^<2+>介导的细胞过程的第二个使者。假设是CADPR在体内的重要sorce,EY信号中性粒细胞功能,调节[Ca^<2 +>]的机制尚不清楚。 <2+>从渗透性的中性粒细胞中释放,并被8BR-CADPR(CADPR的拮抗剂和FK506和RapaMycin)释放。 I.Chemoattractans-and β-nad^+-induced Ycin, nad… More ASE and SEVERAL NUCLEOSIDE TRANSPORTER (NT) INHIBITORS. ENT_1, CNT_2 Ynthesized ExtraCellulary by CD38 Transported Into The Cells THE CELLS THE CD38 THE CELLS THE CD38 THE CELLS THE CELLS细胞细胞细胞细胞细胞细胞细胞的细胞细胞cels cel的一定依赖性过程,是持续的Ca^<2+> inutrophils所必需的。人嗜中性粒细胞的预测枯萎了EGTA或8BR -CADPR或8BR -cADPR,themotsxis sigtlp或paf。同样,用FK506,抗CD38抗体,NADase和NT抑制剂对中性粒细胞的治疗将其阻塞至FMLP或PAF,这些结果表明,在Ca^<2+>移动中,对FMLP的Neuthil趋化,CADPR通过产生CADPR来控制中性粒细胞趋化因素,并作为对临床病理学,CADPR,CD38和NTS抑制新型药物靶标的潜在应用在慢性膜和神经脱发疾病中的临床病理学的批判性调节剂。较少的

项目成果

期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Interleukin-1 inhibits voltage-dependent P/Q-type Ca^<2+> channel associated with the inhibition of the rise of intracellular free Ca^<2+> concentration and catecholamine release in adrenal chromaffiin cells.
Interleukin-1抑制电压依赖性P/Q型Ca^2通道,其与抑制肾上腺嗜铬细胞中细胞内游离Ca^2浓度的升高和儿茶酚胺释放相关。
ヌクレオチドトランスポーターの新しい機能
核苷酸转运蛋白的新功能
  • DOI:
  • 发表时间:
    2004
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Izumi;H.;H;Date;Mizuta;K.;Nakamura;I.;Kuchiiwa;S.;森田 克也
  • 通讯作者:
    森田 克也
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MORITA Katsuya其他文献

MORITA Katsuya的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MORITA Katsuya', 18)}}的其他基金

Development of mechanism-based novel medicaments to pain in advanced cancer
开发基于机制的新型药物来治疗晚期癌症疼痛
  • 批准号:
    22390349
  • 财政年份:
    2010
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Identification of tumor-cell producing novel endogenous analgesic substance
肿瘤细胞产生新型内源性镇痛物质的鉴定
  • 批准号:
    22659337
  • 财政年份:
    2010
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Evidence of a role for cyclic ADP-ribose in pain transduction in spinal cord
环 ADP-核糖在脊髓疼痛传导中作用的证据
  • 批准号:
    18592036
  • 财政年份:
    2006
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanisms of cyclic ADP-ribose-induced Ca^<2+> mobilization and its physiological role
环ADP核糖诱导Ca^2动员机制及其生理作用
  • 批准号:
    13671939
  • 财政年份:
    2001
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Physiological role of cyclic ADP-ribose a novel endogenous agonist of ryanodine receptors
环ADP-核糖作为兰尼碱受体的新型内源性激动剂的生理作用
  • 批准号:
    10470390
  • 财政年份:
    1998
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)

相似国自然基金

转录因子ELK1在人类中性粒细胞谱系决定过程中的分子机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Investigating the Ability of Human Blood Neutrophils to Kill Cancer
研究人类血液中性粒细胞杀死癌症的能力
  • 批准号:
    10648774
  • 财政年份:
    2023
  • 资助金额:
    $ 1.92万
  • 项目类别:
Deciphering the mechanism of SHIP1 regulation in human neutrophils
破译 SHIP1 在人类中性粒细胞中的调节机制
  • 批准号:
    10434928
  • 财政年份:
    2021
  • 资助金额:
    $ 1.92万
  • 项目类别:
Deciphering the mechanism of SHIP1 regulation in human neutrophils
破译 SHIP1 在人类中性粒细胞中的调节机制
  • 批准号:
    10623312
  • 财政年份:
    2021
  • 资助金额:
    $ 1.92万
  • 项目类别:
Deciphering the mechanism of SHIP1 regulation in human neutrophils
破译 SHIP1 在人类中性粒细胞中的调节机制
  • 批准号:
    10280943
  • 财政年份:
    2021
  • 资助金额:
    $ 1.92万
  • 项目类别:
Deciphering the mechanism of SHIP1 regulation in human neutrophils
破译 SHIP1 在人类中性粒细胞中的调节机制
  • 批准号:
    10582013
  • 财政年份:
    2021
  • 资助金额:
    $ 1.92万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了